Navigation Links
Oncothyreon announces issuance of patent for PX-867
Date:3/20/2008

have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to filing an IND for PX-866, future clinical development plans for PX-866, and plans to seek a collaboration partner for PX-867. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of PX-866 and PX-867, and the likelihood of achieving a collaboration agreement for PX-867. There can be no guarantee that the results of preclinical studies will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon to present at upcoming investment conferences
2. Oncothyreon reports full year and fourth quarter 2007 financial results
3. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
4. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
5. Oncothyreon launches new corporate website
6. Oncothyreon to present at BIO CEO & Investor Conference
7. Oncothyreon highlights corporate and clinical objectives for 2008
8. Biomira announces plan to change name to Oncothyreon
9. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
10. Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up
11. BioMS Medical Announces 2007 Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... CORAL SPRINGS, Florida , September 19, 2014 /PRNewswire/ ... biotech companies release latest developments, patents and results of ... (OTC: GNSZ), Eli Lilly and Company (NYSE: ... ), Celgene Corporation (NASDAQ: CELG ) and ... (OTCQB: GNSZ), a leader in developing prodrug therapeutics for ...
(Date:9/19/2014)... 2014 , The first grants ... Paediatric Endocrinology (ESPE) Meeting  Investment supports innovative ... in the field of growth  , EMD ... Germany , today announced the first recipients of ... awards were announced during a Satellite Symposium organized by ...
(Date:9/18/2014)... About POCT POCT, ... clinical laboratory. It helps in making fast clinical ... medication. POCT is gaining popularity due to the ... as diabetes, heart disease, and obesity. It is ... to minimize errors during the diagnosis of patients. ...
(Date:9/18/2014)... , September 18, 2014 ... ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the ... - Global Strategic Business Report" ... http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the worldwide ... Million by the following Product Segments: ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... a positive third,quarter, the biotech industry continued its upward climb ... the state of the economy,and interest rate jitters as the ... Index, for example, rose an impressive 6.1% in,October -- in ... ahead of the,DJIA which was unchanged. "Entering the final ...
... COLUMBIA, Md., Nov. 1 Martek Biosciences,Corporation (Nasdaq: ... in the United,States District Court in Wilmington, Delaware, ... a permanent injunction in Martek,s favor,against the defendants ... Lonza, Ltd., Nutrinova Inc. and Nutrinova Nutrition Specialties ...
... provide free home caregiving to disabled veterans, ... its,2007 We Care For Veterans campaign to honor ... qualified disabled veterans. (Logo: http://www.newscom.com/cgi-bin/prnh/20070521/LAM004ALOGO ) ... are,donating 20 hours each of free in-home care ...
Cached Biology Technology:Biotech Continues Upward Climb in October 2Biotech Continues Upward Climb in October 3Biotech Continues Upward Climb in October 4Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 2Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 3Homewatch CareGivers Launches 2007 We Care For Veterans Campaign 2
(Date:9/21/2014)... working at the University of California, San Diego, have ... marks that control the activity of genes based on ... results from its application to human embryonic cells in ... September 21. , "All of our cells have the ... functions," said John Whitaker, lead author of the report. ...
(Date:9/19/2014)... Call it the Jimmy Durante of dinosaurs ... nasal profile. The new dinosaur, named Rhinorex ... University and Brigham Young University, lived in what ... during the Late Cretaceous period. , Rhinorex, which ... and a close relative of other Cretaceous hadrosaurs ...
(Date:9/19/2014)... species which over thousands of years has adapted to the ... that makes the cold dangerous for you. , This is ... and the cold provoking substance, called nonylphenol, comes from the ... suspected of being a endocrine disruptor, but when entering the ... ability to protect the cells in its body from cold ...
Breaking Biology News(10 mins):Program predicts placement of chemical tags that control gene activity 2New hadrosaur noses into spotlight 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... Researchers have been unable to build an ideal photonic ... ultrafast optical computers. But now, University of Utah chemists ... with the ideal, diamond-like structure: They are found in ... Brazil. It appears that a simple creature like ...
... of the greatest zoological mysteries for over a century. ... puzzling crustaceans, despite the plethora of these larvae in ... what y- larvae grow up to be. A study ... reports the transformation of the larvae into a previously ...
... the Great Lakes have prompted the need to better ... collaborative project is aimed at improving information for beach ... close beaches to protect public health. This collaborative effort ... and other federal, state and local agencies. ...
Cached Biology News:The photonic beetle 2The photonic beetle 3The photonic beetle 4The photonic beetle 5Clue to mystery crustacean in parasite form 2To swim or not to swim? 2
... intensely fluorescent and highly photostable FluoSpheres ... in a variety of applications requiring ... signal. Unfortunately, protein- and other macromolecule-labeled ... cause them to bind to non-target ...
Goat polyclonal to Duffy / FY / DARC...
SMVT (N-14)...
... Source: Tritirachium album Description: ... endopeptidase used in a wide range of applications ... peptide bonds mainly following the carboxyl group of ... and is classified as a serine protease. ...
Biology Products: